Shares of Sun Pharmaceutical Industries declined 1.26% to Rs 1,574.40 on Monday. The stock experienced a volume surge and was among the top losers on the Nifty 50 index at 12:43 pm.
Financial Overview
The company's financial performance reveals the following trends based on consolidated figures:
Quarterly Results:
For the quarter-ending June 2025, Sun Pharmaceutical Industries reported revenue of Rs 13,851.40 Crore and a net profit of Rs 2,302.62 Crore. The EPS stood at Rs 9.50. In comparison:
- Revenue for the quarter-ending March 2025 was Rs 12,958.84 Crore.
- Revenue for the quarter-ending December 2024 was Rs 13,675.46 Crore.
- Revenue for the quarter-ending September 2024 was Rs 13,291.39 Crore.
- Revenue for the quarter-ending June 2024 was Rs 12,652.75 Crore.
- Net profit for the quarter-ending March 2025 was Rs 2,160.64 Crore.
- Net profit for the quarter-ending December 2024 was Rs 2,917.54 Crore.
- Net profit for the quarter-ending September 2024 was Rs 3,030.67 Crore.
- Net profit for the quarter-ending June 2024 was Rs 2,871.25 Crore.
For the year-ending March 2025, the company's revenue was Rs 52,578.44 Crore and net profit was Rs 10,980.10 Crore. The EPS was Rs 45.60, BVPS was Rs 301.00, and ROE was 15.13%. The debt to equity ratio stood at 0.03.
The revenue increased by 8.42 percent in 2025 compared to 2024.
The net profit increased by 13.80 percent in 2025 compared to 2024.
Here is a detailed table:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 33,498.14 Crore | Rs 38,654.49 Crore | Rs 43,885.68 Crore | Rs 48,496.85 Crore | Rs 52,578.44 Crore |
| Net Profit | Rs 2,284.68 Crore | Rs 3,405.82 Crore | Rs 8,560.84 Crore | Rs 9,648.44 Crore | Rs 10,980.10 Crore |
| EPS | Rs 12.10 | Rs 13.60 | Rs 35.30 | Rs 39.90 | Rs 45.60 |
| BVPS | Rs 206.23 | Rs 212.84 | Rs 247.22 | Rs 265.36 | Rs 301.00 |
| ROE | 6.24% | 6.81% | 15.13% | 15.04% | 15.13% |
| Debt to Equity | 0.07 | 0.02 | 0.11 | 0.04 | 0.03 |
The following table summarizes the consolidated income statement:
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales | Rs 33,498 Crore | Rs 38,654 Crore | Rs 43,885 Crore | Rs 48,496 Crore | Rs 52,578 Crore |
| Other Income | Rs 835 Crore | Rs 921 Crore | Rs 634 Crore | Rs 1,354 Crore | Rs 1,965 Crore |
| Total Income | Rs 34,333 Crore | Rs 39,576 Crore | Rs 44,520 Crore | Rs 49,851 Crore | Rs 54,543 Crore |
| Total Expenditure | Rs 31,392 Crore | Rs 34,967 Crore | Rs 34,939 Crore | Rs 38,524 Crore | Rs 40,559 Crore |
| EBIT | Rs 2,940 Crore | Rs 4,608 Crore | Rs 9,580 Crore | Rs 11,326 Crore | Rs 13,983 Crore |
| Interest | Rs 141 Crore | Rs 127 Crore | Rs 172 Crore | Rs 238 Crore | Rs 231 Crore |
| Tax | Rs 514 Crore | Rs 1,075 Crore | Rs 847 Crore | Rs 1,439 Crore | Rs 2,772 Crore |
| Net Profit | Rs 2,284 Crore | Rs 3,405 Crore | Rs 8,560 Crore | Rs 9,648 Crore | Rs 10,980 Crore |
Cash flow details are as follows:
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Operating Activities | Rs 6,170 Crore | Rs 8,984 Crore | Rs 4,959 Crore | Rs 12,134 Crore | Rs 14,072 Crore |
| Investing Activities | Rs 536 Crore | Rs -5,724 Crore | Rs -7,943 Crore | Rs -690 Crore | Rs -5,306 Crore |
| Financing Activities | Rs -5,980 Crore | Rs -5,193 Crore | Rs 2,376 Crore | Rs -6,710 Crore | Rs -7,905 Crore |
| Others | Rs -129 Crore | Rs 168 Crore | Rs 723 Crore | Rs -72 Crore | Rs 123 Crore |
| Net Cash Flow | Rs 596 Crore | Rs -1,764 Crore | Rs 115 Crore | Rs 4,661 Crore | Rs 983 Crore |
Key balance sheet figures are:
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Share Capital | Rs 239 Crore | Rs 239 Crore | Rs 239 Crore | Rs 239 Crore | Rs 239 Crore |
| Reserves & Surplus | Rs 46,222 Crore | Rs 47,771 Crore | Rs 55,755 Crore | Rs 63,426 Crore | Rs 71,978 Crore |
| Current Liabilities | Rs 16,145 Crore | Rs 17,200 Crore | Rs 19,907 Crore | Rs 16,984 Crore | Rs 18,194 Crore |
| Other Liabilities | Rs 5,058 Crore | Rs 4,588 Crore | Rs 4,841 Crore | Rs 4,811 Crore | Rs 1,688 Crore |
| Total Liabilities | Rs 67,666 Crore | Rs 69,799 Crore | Rs 80,743 Crore | Rs 85,462 Crore | Rs 92,100 Crore |
| Fixed Assets | Rs 16,832 Crore | Rs 17,197 Crore | Rs 20,680 Crore | Rs 19,966 Crore | Rs 20,290 Crore |
| Current Assets | Rs 30,442 Crore | Rs 35,014 Crore | Rs 39,883 Crore | Rs 43,474 Crore | Rs 52,624 Crore |
| Other Assets | Rs 20,392 Crore | Rs 17,587 Crore | Rs 20,179 Crore | Rs 22,021 Crore | Rs 19,185 Crore |
| Total Assets | Rs 67,666 Crore | Rs 69,799 Crore | Rs 80,743 Crore | Rs 85,462 Crore | Rs 92,100 Crore |
| Contingent Liabilities | Rs 7,057 Crore | Rs 6,756 Crore | Rs 7,903 Crore | Rs 6,343 Crore | Rs 6,777 Crore |
Key financial ratios for Sun Pharmaceutical Industries are:
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | Rs 12.10 | Rs 13.60 | Rs 35.30 | Rs 39.90 | Rs 45.60 |
| Diluted Eps (Rs.) | Rs 12.10 | Rs 13.60 | Rs 35.30 | Rs 39.90 | Rs 45.60 |
| Book Value /Share (Rs.) | Rs 206.23 | Rs 212.84 | Rs 247.22 | Rs 265.36 | Rs 301.00 |
| Dividend/Share (Rs.) | Rs 7.50 | Rs 10.00 | Rs 11.50 | Rs 13.50 | Rs 16.00 |
| Face Value | 1 | 1 | 1 | 1 | 1 |
| Gross Profit Margin (%) | 27.84% | 29.28% | 27.98% | 29.64% | 32.78% |
| Operating Margin (%) | 21.63% | 23.73% | 22.22% | 24.37% | 27.88% |
| Net Profit Margin (%) | 6.82% | 8.81% | 19.50% | 19.89% | 20.88% |
| Return on Equity (%) | 6.24% | 6.81% | 15.13% | 15.04% | 15.13% |
| ROCE (%) | 14.06% | 17.44% | 16.02% | 17.26% | 19.83% |
| Return On Assets (%) | 4.29% | 4.68% | 10.49% | 11.20% | 11.86% |
| Current Ratio (X) | 1.89 | 2.04 | 2.00 | 2.56 | 2.89 |
| Quick Ratio (X) | 1.33 | 1.51 | 1.48 | 1.98 | 2.33 |
| Debt to Equity (x) | 0.07 | 0.02 | 0.11 | 0.04 | 0.03 |
| Interest Coverage Ratios (X) | 65.95 | 88.88 | 71.40 | 60.29 | 74.50 |
| Asset Turnover Ratio (%) | 0.49 | 0.56 | 0.58 | 0.58 | 0.59 |
| Inventory Turnover Ratio (X) | 0.73 | 0.78 | 0.80 | 4.69 | 5.18 |
| 3 Yr CAGR Sales (%) | 12.61 | 15.32 | 15.60 | 20.32 | 16.63 |
| 3 Yr CAGR Net Profit (%) | -6.86 | 3.02 | 42.99 | 105.50 | 79.55 |
| P/E (x) | 49.40 | 67.26 | 27.85 | 40.62 | 38.04 |
| P/B (x) | 3.09 | 4.57 | 4.21 | 6.11 | 5.77 |
| EV/EBITDA (x) | 15.36 | 19.30 | 19.51 | 26.75 | 23.62 |
| P/S (x) | 4.28 | 5.68 | 5.37 | 8.02 | 7.92 |
The company has announced several analyst/investor meetings, as per regulatory filings with the BSE. A transcript of the Q1 FY26 earnings call was also announced on August 6, 2025.
Dividends:
Recent dividend announcements include:
- Final Dividend: Rs 5.50 per share (550%) with effective date July 7, 2025.
- Interim Dividend: Rs 10.50 per share (1050%) with effective date February 6, 2025.
The company has issued bonus shares in the past, including:
- Bonus ratio of 1:1, with ex-bonus date of July 29, 2013.
- Bonus ratio of 1:1, with ex-bonus date of May 27, 2004.
- Bonus ratio of 2:1, with ex-bonus date of March 6, 2000.
The company has split its stock in the past, including:
- Stock split from Rs 5 to Rs 1, with ex-split date of November 25, 2010.
- Stock split from Rs 10 to Rs 5, with ex-split date of January 13, 2003.
Moneycontrol analysis on August 26, 2025, indicated a very bearish sentiment for the stock.
With the stock currently trading at Rs 1,574.40, Sun Pharmaceutical Industries experienced a decline amid high trading volume and faces bearish market sentiment.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
